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It is possible that reduced function of DNA repair and cell-cycle control genes increases the individual
susceptibility to malignant melanoma. As CHEK2 is a cell-cycle master controller, we tested the hypothesis that
heterozygosity for the frameshift alteration CHEK2*1100delC is associated with increased risk of malignant
melanoma. First, we performed case–control studies of 1,152 Danish and 752 German individuals with malignant
melanoma compared with 9,142 Danish and 3,718 German controls. Second, we performed a meta-analysis of
CHEK2*1100delC and malignant melanoma, involving 2,619 cases and 17,481 controls. Third, we examined the
risk of malignant melanoma associated with CHEK2*1100delC heterozygosity in an analysis stratified for sun
exposure, as well as for subtype and location on the body. The odds ratios for malignant melanoma for
CHEK2*1100del heterozygotes compared with those for noncarriers were 2.01 (95% confidence interval (CI),
1.03–3.91) in Danes, 1.42 (95% CI, 0.46–4.31) in Germans, and 1.79 (95% CI, 1.02–3.17) in Danes and Germans
combined. In a meta-analysis, the odds ratio of malignant melanoma for CHEK2*1100delC heterozygotes
compared with that for noncarriers was 1.81 (95% CI, 1.07–3.05). Stratifications did not alter these results.
CHEK2*1100delC heterozygotes have a twofold risk of malignant melanoma compared with noncarriers.
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INTRODUCTION
UV irradiation leads to three major classes of DNA lesions:
cyclobutane pyrimidine dimers, pyrimidine 6–4 pyrimidone
photoproducts, and their Dewar isomers (Rastogi et al.,
2010). These lesions cause a problem during DNA transcrip-
tion and/or replication, wherein they block DNA replication
forks leading to DNA double-strand breaks (Rastogi et al.,
2010). Furthermore, DNA double-strand breaks can also
occur during repair of UV-induced single-strand breaks
passing through base-excision repair (Vilenchik and Knud-
son, 2003). To protect genomic integrity, cells have over 150
DNA repair enzymes that identify and repair various types of
DNA damage (Wood et al., 2005; Branzei and Foiani, 2008).
Among these is the nuclear CHEK2 protein, encoded by the
CHEK2 gene.
CHEK2 is involved in recognition of DNA double-strand
breakage and in activation of downstream targets such as p53
and BRCA1 causing cell-cycle arrest, DNA repair, and
possibly apoptosis (Bartek and Lukas, 2003). CHEK2 is
upregulated in response to UV exposure with peak levels
of 4–8 hours following UV exposure (Yajima et al., 2009),
suggesting a key role of the protein in UV damage control.
Although it is well recognized that individuals heterozygous
for the nonfunctioning frameshift CHEK2*1100delC germline
alteration have a two- to threefold increased risk of
developing breast cancer (Vahteristo et al., 2002; Schutte
et al., 2003; The CHEK2*1100delC Breast Cancer Association
Consortium, 2004; Einarsdottir et al., 2006; Cybulski et al.,
2007; Weischer et al., 2007, 2008), only two studies have
examined the association of CHEK2*1100delC heterozygos-
ity with risk of malignant melanoma, with limited statistical
power (Weischer et al., 2007; Debniak et al., 2008). Thus,
more studies are needed to understand the role of
CHEK2*1100delC in malignant melanoma.
We tested the hypothesis that CHEK2*1100delC hetero-
zygosity is associated with increased risk of malignant
melanoma. To do so, we first carried out case–control studies
on 1,152 Danish and 752 German individuals with malignant
melanoma compared with 9,142 Danish and 3,718
German controls. Second, we performed a meta-analysis
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of CHEK2*1100delC and malignant melanoma, involving
2,619 cases and 17,481 controls. Third, we examined the risk
of developing malignant melanoma associated with
CHEK2*1100delC heterozygosity in analyses stratified for
history of sun exposure and for location and subtype of the
malignant melanoma, as individuals and locations on the
body exposed to intermittent, as opposed to, chronic sun
exposure have a higher likelihood of developing malignant
melanoma (Caini et al., 2009; Gerstenblith et al., 2010;
Newton-Bishop et al., 2010), and as subtypes of malignant
melanoma might differ in their molecular pathogenesis
(Curtin et al., 2005).
RESULTS
Case–control studies
We studied 1,152 unselected Danish and 752 unselected
German patients with malignant melanoma and compared
them with 9,142 Danish and 3,718 German controls
(Table 1). The distribution of genotypes among the controls
was in the Hardy–Weinberg equilibrium in both the
nationalities (Danes P¼0.81 and Germans P¼0.91). Among
cases, 11 were CHEK2*1100delC heterozygotes. Of these, six
Danes and one German were women.
The odds ratios (ORs) for malignant melanoma among
CHEK2*1100delC heterozygotes compared with noncarriers
were 2.01 (95% confidence interval (CI): 1.03–3.91) in Danes,
1.41 (95% CI: 0.46–4.31) in Germans, and 1.79 (95% CI:
1.02–3.17) in Danes and Germans combined (Table 2; Danes
vs. Germans: P¼ 0.59). Age and gender did not interact with
CHEK2*1100delC heterozygosity on risk of malignant mela-
noma (P¼0.84 and P¼ 0.82; tested in Danes only).
CHEK2*1100delC heterozygosity was not associated
with history of sun exposure and location and subtype of
malignant melanoma (Supplementary Table S1 online).
Meta-analysis
The characteristics of the 2,619 cases with malignant
melanoma and the 17,481 controls in the four studies are
listed in Table 3.
Using a fixed effect model, we found an aggregated OR
for malignant melanoma of 1.81 (95% CI: 1.07–3.05) for
CHEK2*1100delC heterozygotes compared with noncarriers
(Figure 1). The funnel plot showed no evidence of publication
bias. I2-value was 0% (95% CI: 0–85) among studies,
indicating no heterogeneity (Higgins et al., 2003).
Stratified analysis
Supplementary Table S2 online shows age- and gender-
adjusted ORs for malignant melanoma for CHEK2*1100delC
heterozygotes compared with noncarriers stratified by history
of sun exposure and location and subtype of malignant
melanoma in Danes; this information was available for cases
only and not for controls. Each stratum of cases was
compared with the same group of 9,142 controls. We
observed increased ORs of malignant melanoma associated
with CHEK2*1100delC heterozygotes compared with non-
carriers in all strata, although some estimates were not
statistically significant (Supplementary Table S2 online).
DISCUSSION
In Danish and German case–control studies and in the meta-
analysis, we found a twofold increased risk of malignant
melanoma for individuals heterozygous for CHEK2*1100-
delC compared with noncarriers.
Mechanistically, it seems plausible that CHEK2*1100delC
would increase the risk of malignant melanoma, because
heterozygous individuals have an impaired ability to recog-
nize and repair UV-induced DNA double-strand breaks
(Bartek and Lukas, 2003; Rastogi et al., 2010). As a
consequence, damaged cells are allowed to proliferate,
thereby increasing the risk of oncogenic transformation
toward a malignant phenotype.
The twofold risk of malignant melanoma among
CHEK2*1100delC heterozygotes compared with noncarriers
is similar to that observed for polymorphisms in MC1R.
MC1R encodes the melanocortin-1 receptor that is situated
on the outside of melanocytes. A series of polymorphisms
have been identified in MC1R that reduce response to
stimulation of eumelanin production, causing melanocytes to
Table 1. Characteristics of participants
Danish German
Cases Controls Cases Controls1
Participants, n 1,152 9,142 752 3,718
CHEK2*1100delC genotype, n (%)
Noncarriers 1,141 (99.0) 9,097 (99.5) 752 (99.5) 3,704 (99.6)
Heterozygotes 11 (1.0) 45 (0.5) 4 (0.5) 14 (0.4)
Homozygotes 0 (0) 0 (0) 0 (0) 0 (0)
Age, years
Median (IQR) 54 (42–65) 60 (47–70) 55 (43–65) NA





Abbreviations: IQR, interquartile range; NA, not available.
1From references (Dufault et al., 2004; The CHEK2*1100delC Breast
Cancer Association Consortium, 2004; Rashid et al., 2005; Scharrer et al.,
2010).









All 1,889/12,801 15/59 1.79 (1.02–3.17)1
Danes 1,141/9,097 11/45 2.01 (1.03–3.91)2 0.59
Germans 748/3,704 4/14 1.41 (0.46–4.31)3
1Mantel–Haentzel statistics analysis adjusted for study weight.
2Logistic regression analysis adjusted for age at ascertainment and gender.
3Odds ratio calculated by w2-test.
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produce mostly pheomelanin, which leads to lighter skin,
hair, and eye color. A recent meta-analysis of non-red hair
color and red hair color polymorphisms of MC1R reported
aggregated ORs for malignant melanoma of 1.29 (95% CI,
1.10–1.51) and 2.44 (95% CI, 1.72–3.46; Williams et al.,
2011). The twofold risk of malignant melanoma in
CHEK2*1100delC heterozygotes compared with noncarriers
observed in this study is similar to the two- to threefold
increased risk reported for breast cancer (The CHEK2*1100-
delC Breast Cancer Association Consortium, 2004; Weischer
et al., 2008).
As the majority of our cases had sporadic malignant
melanoma, we did not test for CDKN2A mutations, as these
are mostly found among individuals with familial history of the
disease. At least 30 different functional mutations in CDKN2A
have been reported (Orlow et al., 2007). Their combined
frequency is less than 1% in malignant melanoma patients not
selected for familial history of disease, and even less in
controls, limiting the possibility of identifying more than just a
few individuals carrying the same variant (Orlow et al., 2007).
In addition, we did not examine mutations in pigmentation
pathways, as these have been thoroughly examined by others
(Landi et al., 2006; Gudbjartsson et al., 2008; Raimondi et al.,
2008; Gerstenblith et al., 2010; Newton-Bishop and Gruis,
2010; Williams et al., 2011).
Our study has several strengths. First, we studied both
Danes and Germans and found similar results. Second, in a
meta-analysis also including a Polish and an additional
Danish study, the overall result was similar to that observed
in the present two case–control studies. Finally, because of
the fact that we reran the genotype test several times, we
succeeded in genotyping 99.9% of all available participants.
The limitations of our study include reduced statistical power
in the stratified analyses and selection of German controls.
These were found through literature searches and were
chosen from four different studies. Thus, it is slightly
concerning that the frequency of CHEK2*1100delC differed
between the different control groups (Rashid et al., 2005:
0.9 and 0%; Scharrer et al., 2010: 0%; Dufualt et al., 2004:
0.46%, and The CHEK2*1100delC Breast Cancer Association
Consortium, 2004: 0.15% and 0.25%, respectively).
In addition, for 502 controls, the gender was unknown;
however, the remaining controls (N¼3,216) were all
women, which means that at least 86% of the German
controls were female.
In conclusion, CHEK2*1100delC heterozygosity doubled
the risk of malignant melanoma.
MATERIALS AND METHODS
Case–control studies
Study populations. Cases: Patients were recruited from the
Department of Plastic Surgery, Herlev Hospital, Copenhagen
University Hospital, Denmark (n¼ 469); from the Department of
Oncology, Aarhus University Hospital, Denmark (n¼ 361); the
Department of Plastic Surgery, Rigshospitalet, Copenhagen Uni-
versity Hospital, Denmark (n¼ 188); the Department of Oncology,
Odense University Hospital, Denmark (n¼ 134); and from the
Department of Dermatology, Eberhard Karls University, Tu¨bingen,
Germany (n¼ 752). All patients were consecutively recruited from
2008 to 2010. On the day of the examination, the patients gave
blood for DNA extraction and filled in questionnaires regarding their
lifestyle and medical history. The questionnaire asked for informa-
tion on sun exposure, requesting details about the number of
childhood sunburns, number of vacations to sunny destinations
within the last 10 years, and use of sunbeds within the last 10 years.
Table 3. Characteristics of studies on CHEK2*1100delC heterozygosity and risk of malignant melanoma
Overall Heterozygotes
Cases Controls Cases Controls







Weischer et al., 2007 88 (98.9) 649 (99.5) 1 (1.1) 3 (0.5) PR GP Genescan Denmark
Debniak et al., 2008 627 (99.7) 4,621 (99.8) 2 (0.3) 8 (0.2) CC Hospital RFLP Poland
Weischer, 2011 1,152 (99.0) 8,493 (99.5) 11 (1.0) 42 (0.5) CC Hospital Taqman Denmark
Weischer, 2011 752 (99.5) 3,718 (99.6) 4 (0.5) 14 (0.4) CC Hospital Taqman Germany
Abbreviations: CC, case–control study; GP, general population; PR, prospective cohort study; RFLP, restriction fragment length polymorphism.















Odds ratio (95% CI)
Figure 1. Meta-analysis of studies of CHEK2*1100delC heterozygosity and
risk of malignant melanoma. Studies are adjusted for and ranked by increasing
weight. Boxes indicate study weight, and horizontal lines indicate 95%
confidence interval (CI). The aggregated fixed effect odds ratio (OR) is shown
as a diamond. The perforated vertical line indicates the aggregated OR. To
avoid counting the same controls twice, controls were divided between the
Weischer et al., 2007 and the present Danish case–control study (Weischer
et al., 2011) as shown in Table 3. Therefore, the OR of the Weischer et al.
2011 Danish case–control study differs slightly from that in Table 2.
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On the day of the examination, a physician counted nevi,
diagnosed the presence or absence of solar keratosis, and noted
the location of the malignant melanoma. The examining physicians
were highly trained dermatologists, plastic surgeons, and oncolo-
gists. All participants gave written informed consent. Information on
sun exposure was only available for cases. Confirmation of diagnosis
of malignant melanoma for the Danish cases was obtained from The
Danish Melanoma Group, a nationwide registry collecting prospec-
tive data on all Danish patients treated for malignant melanoma,
including in situ lesions (www.melanoma.dk). Clinical and patho-
logical data on the German patients were obtained from the
electronic database of the Central Malignant Melanoma Registry,
which is a German nationwide hospital-based registry.
Controls: Controls were selected from the Copenhagen City Heart
Study, a prospective study of the general population initiated in
1976–1978 with follow-up examinations in 1981–1983, 1991–1994,
and 2001–2003. The study included 9,244 participants who reflect
the adult Danish population aged 20–80þ years. Although the study
was named after its initial purpose, namely, to examine heart
disease, participants were not selected according to disease status
but were randomly chosen from the National Danish Civil
Registration System and were invited to participate. On the day of
the examination, participants filled in questionnaires, were physi-
cally examined, and gave blood for DNA analysis. Participants were
monitored for development of malignant melanoma (International
Classification of Disease 10 codes C43.0–C43.9) from 1 April 1968
to May 2009 (Bojesen et al., 2003). Follow-up was 100%
complete; that is, we did not lose track of even a single individual.
Diagnoses of malignant melanoma were obtained from the Danish
Cancer Registry, which identifies 98% of all cancers in Denmark
(Storm et al., 1997). A total of 9,142 participants who did not
develop malignant melanoma during follow-up were included as
controls. German controls were found in the literature through a
computer-based search of PubMED using the keyword ‘‘CHEK2’’
and ‘‘Germany’’. We identified four studies with a total of 3,718
controls (Dufault et al., 2004; The CHEK2*1100delC Breast
Cancer Association Consortium, 2004; Rashid et al., 2005;
Scharrer et al., 2010).
Meta-analysis
Search strategy and selection criteria. Cohort and case–control
studies of CHEK2*1100delC and risk of malignant melanoma
published before 1 February 2011 were identified through a
computer-based search of PubMED, EMBASE, and Web of Science
using the keywords ‘‘CHEK2’’, ‘‘CHEK2*1100delC’’, and ‘‘CHK2’’.
This search identified seven studies (Cybulski et al., 2004; Debniak
et al., 2004, 2008; Huang et al., 2004; Thompson et al., 2006;
Cybulski, 2007; Weischer et al., 2007). For cases, the inclusion
criterion for this meta-analysis was a diagnosis of malignant
melanoma, which could not be attributed to a known multicancer
syndrome, and, for controls, the criterion was an absence of
malignant melanoma. Both cases and controls were included only
if they were of Northern or Eastern European descent and had
CHEK2*1100delC genotype ascertained. We excluded five of the
original seven identified studies (Cybulski et al., 2004; Debniak
et al., 2004; Huang et al., 2004; Thompson et al., 2006; Cybulski,
2007). Studies were excluded if they were double publications
(Cybulski et al., 2004; Debniak et al., 2004; Cybulski, 2007), if cases
were ascertained on the background of another cancer (Thompson
et al., 2006), or if cases had malignant melanoma as part of a
multicancer syndrome (Huang et al., 2004). Cases and controls were
counted only once. The Danish controls in the present paper have
been presented previously (Weischer et al., 2007); therefore, to
avoid these controls being counted twice, controls were separated
into two groups according to the number of cases in the present and
previous study (Weischer et al., 2007).
Data abstraction. From each study we extracted information on
author names, year, study design, ascertainment of cases, genotyping
method, nationality, and genotype frequency. For the paper by
Weischer et al. (2007) we obtained information from the authors on
the number of participants with malignant melanoma and the
CHEK2*1100delC carrier status of participants, as these data were
not provided in the original publication.
Genotyping. Leukocyte DNA was extracted from peripheral blood
to amplify a 162-bp long fragment flanking the CHEK2 gene by PCR
using the forward primer 50-GGCAGACTATGTTAATCTTTTTATTTT
ATGG-30 and reverse primer 50-CAAGAACTTCAGGCGCCAAGT-30.
CHEK2*1100delC carrier status was detected using a TaqMan-based
assay (Applied Biosystems, Foster City, CA) using the following
probes: wild-type allele 50-VIC-TTTAGATTACTGATTTTGGGC-30
and mutated allele 50-FAM-TTAGATTATGATTTTGGGCAC-30. In
each run, two heterozygous samples were added as positive controls,
one noncarrier was run as a negative control, and water was run as a
non-template control. To reduce the number of no-calls to a minimum,
two rounds of reruns were performed. We genotyped more than
99.9% of the participants. All identified heterozygotes were validated
by DNA sequencing. The Danish and German controls were
genotyped as described previously (The CHEK2*1100delC Breast
Cancer Association Consortium, 2004; Dufault et al., 2004; Rashid
et al., 2005; Weischer et al., 2007; Scharrer et al., 2010).
Statistical analyses
Case–control studies. We used the statistical software STATA
(STATA/SE 11.1 for Windows, Stata Corp, College Station, TX).
We examined Hardy–Weinberg equilibrium using the w2-test.
Using logistic regression analysis, we calculated gender- and
age-adjusted OR for the Danish participants. For the German
participants we calculated an unadjusted OR using the w2-test. For
Danes and Germans combined, we calculated a fixed-effect OR
adjusted for study size using Mantel–Haentzel statistics (see below).
To test whether the Danish-only and German-only ORs were
significantly different, we used the Z-test described by Altman and
Bland (2003). This test requires that the two estimates be
independent, a requirement that we believe was fulfilled, as there
was no overlap among cases or controls.
Meta-analysis. Odds ratios for CHEK2*1100delC heterozygotes
compared with those for noncarriers were calculated as a fixed effect
measure using Mantel–Haentzel statistics. In the fixed effect model,
we assumed that all studies come from a common population and
that the effect size is not significantly different among the different
studies. The model was adjusted for study weight. We tested for
publication bias graphically by using funnel plots, in which the
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log(OR) is plotted against the standard error (log[OR]) to form a
simple scatter plot. An asymmetric plot would indicate publication
bias, but this was not observed. We tested for heterogeneity between
studies using I2 statistics.
Stratified analysis. We included Danish cases and controls with
recorded histories on childhood sunburn, vacations to sunny
destinations, use of sunbeds, solar keratosis, and malignant mela-
noma type and location. Participant numbers differ from the number
of cases in Table 1 because of the lack of complete information or
unknown status in questionnaires. Odds ratios were obtained by
logistic regression adjusting for age, gender, and hospital.
Ethics
Participants gave written informed consent. Danish (KA-02152,
KF-100.2039/91, KF-01-144/01) and German (376/2007O1) ethical
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